Search research articles
Contact Us
Filters
Showing results (61-70 of 75) with videos related to
Page
of 8
Sort By:
European Journal of Pharmacology
|
April 26, 2017
Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents
Rick L Pieschl, Regina Miller, Kelli M Jones, et al.
Plos One
|
July 29, 2016
The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia
Linda J Bristow, Amy E Easton, Yu-Wen Li, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 27, 2004
Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats
Snjezana Lelas, Harvey Wong, Yu-Wen Li, et al.
ACS Medicinal Chemistry Letters
|
March 18, 2016
Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5
Fukang Yang, Lawrence B Snyder, Anand Balakrishnan, et al.
Journal of Medicinal Chemistry
|
December 4, 2009
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist
Richard A Hartz, Vijay T Ahuja, Xiaoliang Zhuo, et al.
ACS Chemical Neuroscience
|
October 18, 2016
Discovery of Indazoles as Potent, Orally Active Dual Neurokinin 1 Receptor Antagonists and Serotonin Transporter Inhibitors for the Treatment of Depression
Andrew P Degnan, George O Tora, Hong Huang, et al.
Journal of Medicinal Chemistry
|
June 26, 2009
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists
Richard A Hartz, Vijay T Ahuja, Maria Rafalski, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 27, 2012
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agents
Jeffrey A Deskus, Douglas D Dischino, Ronald J Mattson, et al.
Journal of Medicinal Chemistry
|
June 26, 2009
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists
Richard A Hartz, Vijay T Ahuja, Argyrios G Arvanitis, et al.
Journal of Medicinal Chemistry
|
December 23, 2016
Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P<sub>1</sub> Receptor Modulator
Michael G Yang, Zili Xiao, T G Murali Dhar, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 75) with videos related to
Sort By:
Page
of 8
European Journal of Pharmacology
|
April 26, 2017
Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents
Rick L Pieschl, Regina Miller, Kelli M Jones, et al.
Plos One
|
July 29, 2016
The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia
Linda J Bristow, Amy E Easton, Yu-Wen Li, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 27, 2004
Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats
Snjezana Lelas, Harvey Wong, Yu-Wen Li, et al.
ACS Medicinal Chemistry Letters
|
March 18, 2016
Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5
Fukang Yang, Lawrence B Snyder, Anand Balakrishnan, et al.
Journal of Medicinal Chemistry
|
December 4, 2009
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist
Richard A Hartz, Vijay T Ahuja, Xiaoliang Zhuo, et al.
ACS Chemical Neuroscience
|
October 18, 2016
Discovery of Indazoles as Potent, Orally Active Dual Neurokinin 1 Receptor Antagonists and Serotonin Transporter Inhibitors for the Treatment of Depression
Andrew P Degnan, George O Tora, Hong Huang, et al.
Journal of Medicinal Chemistry
|
June 26, 2009
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists
Richard A Hartz, Vijay T Ahuja, Maria Rafalski, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 27, 2012
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agents
Jeffrey A Deskus, Douglas D Dischino, Ronald J Mattson, et al.
Journal of Medicinal Chemistry
|
June 26, 2009
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists
Richard A Hartz, Vijay T Ahuja, Argyrios G Arvanitis, et al.
Journal of Medicinal Chemistry
|
December 23, 2016
Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P<sub>1</sub> Receptor Modulator
Michael G Yang, Zili Xiao, T G Murali Dhar, et al.
Page
of 8